Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
100.27
-0.40 (-0.40%)
At close: Nov 13, 2026, 4:00 PM EST
99.48
-0.79 (-0.79%)
After-hours: Nov 13, 2026, 7:56 PM EST
Halozyme Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,802 | 1,397 | 1,015 | 829.25 | 660.12 | 443.31 | |
Revenue Growth | 45.02% | 37.55% | 22.44% | 25.62% | 48.91% | 65.66% |
Cost of Revenue | 432.55 | 310.26 | 238.47 | 268.72 | 205.91 | 117.09 |
Gross Profit | 1,370 | 1,086 | 776.86 | 560.53 | 454.21 | 326.23 |
Selling, General & Admin | 236.45 | 193.39 | 154.34 | 149.18 | 121.63 | 50.32 |
Amortization of Goodwill & Intangibles | 111.91 | 76.66 | 71.05 | 73.77 | 43.15 | - |
Operating Expenses | 348.36 | 270.05 | 225.38 | 222.96 | 164.77 | 50.32 |
Operating Income | 1,022 | 816.29 | 551.48 | 337.57 | 289.43 | 275.9 |
Interest Expense | -22.05 | -18.13 | -18.1 | -18.76 | -16.95 | -7.53 |
Interest & Investment Income | 7.26 | 18.01 | 12.83 | 10 | 3.88 | 3.36 |
EBT Excluding Unusual Items | 1,007 | 816.17 | 546.21 | 328.81 | 276.36 | 271.74 |
Merger & Restructuring Charges | -13.7 | -13.7 | - | - | -21.9 | - |
Gain (Loss) on Sale of Investments | 1.49 | 3.47 | 10.93 | 6.32 | -2.83 | -2.26 |
Asset Writedown | -48.7 | -48.7 | - | - | - | - |
Other Unusual Items | -5.94 | -5.48 | - | 13.2 | -2.71 | -20.96 |
Pretax Income | 655.01 | 466.88 | 557.13 | 348.33 | 248.92 | 248.52 |
Income Tax Expense | 169.59 | 149.99 | 113.04 | 66.74 | 46.79 | -154.19 |
Net Income | 485.42 | 316.89 | 444.09 | 281.59 | 202.13 | 402.71 |
Net Income to Common | 485.42 | 316.89 | 444.09 | 281.59 | 202.13 | 402.71 |
Net Income Growth | -18.48% | -28.64% | 57.71% | 39.31% | -49.81% | 211.97% |
Shares Outstanding (Basic) | 117 | 120 | 127 | 132 | 137 | 141 |
Shares Outstanding (Diluted) | 122 | 124 | 129 | 134 | 141 | 147 |
Shares Change | -2.62% | -4.26% | -3.56% | -4.56% | -4.21% | 3.77% |
EPS (Basic) | 4.16 | 2.64 | 3.50 | 2.13 | 1.48 | 2.86 |
EPS (Diluted) | 3.97 | 2.56 | 3.43 | 2.10 | 1.44 | 2.74 |
EPS Growth | -16.17% | -25.36% | 63.33% | 45.83% | -47.45% | 201.10% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 885.88 | 644.59 | 468.37 | 373.28 | 235.3 | 297.98 |
Free Cash Flow Per Share | 7.24 | 5.20 | 3.62 | 2.78 | 1.67 | 2.03 |
Gross Margin | 76.00% | 77.78% | 76.51% | 67.59% | 68.81% | 73.59% |
Operating Margin | 56.67% | 58.45% | 54.32% | 40.71% | 43.84% | 62.24% |
Profit Margin | 26.93% | 22.69% | 43.74% | 33.96% | 30.62% | 90.84% |
Free Cash Flow Margin | 49.15% | 46.15% | 46.13% | 45.01% | 35.64% | 67.22% |
EBITDA | 1,140 | 897.84 | 627.09 | 416.93 | 336.07 | 277.3 |
EBITDA Margin | 63.27% | 64.29% | 61.76% | 50.28% | 50.91% | 62.55% |
D&A For EBITDA | 118.88 | 81.55 | 75.61 | 79.36 | 46.64 | 1.4 |
EBIT | 1,022 | 816.29 | 551.48 | 337.57 | 289.43 | 275.9 |
EBIT Margin | 56.67% | 58.45% | 54.32% | 40.71% | 43.84% | 62.24% |
Effective Tax Rate | 25.89% | 32.13% | 20.29% | 19.16% | 18.80% | - |
Revenue as Reported | 1,802 | 1,397 | 1,015 | 829.25 | 660.12 | 443.31 |